This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In MiMedx Group, Inc. To Contact The Firm

NEW YORK, Oct. 11, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MiMedx, Inc. ("MiMedx" or the "Company") (NASDAQ: MDXG) of the November 8, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against MiMedx and certain executives.

(Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

A complaint has been filed on behalf of all persons who purchased or otherwise acquired MiMedx common stock between October 26, 2011 and September 4, 2013 (the "Class Period").

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that throughout the Class Period MiMedx issued false and/or misleading statements and failed to disclose that: (i) the Company was not in possession of the necessary licensing to manufacture certain products and (ii) as a result, the substantial revenue derived from the unapproved products was subject to termination.

On September 4, 2013, the Company announced that it received an "Untitled Letter" from the FDA which stated that MiMedx's Surgical Biologics unit violated the Public Health Service Act by unlawfully manufacturing and marketing drugs at one of its plants.

Following this news, the Company's stock declined $2.21 per share, or over 36%, to close at $3.85 per share on September 4, 2013.

Request more information now by clicking here: www.faruqilaw.com/MDXG.  There is no cost or obligation to you.

Take Action

If you invested in MiMedx stock or options between October 26, 2011 and September 4, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/MDXG.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding MiMedx's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP  369 Lexington Avenue, 10th Floor   New York, NY 10017   Attn:  Richard Gonnello, Esq.   rgonnello@faruqilaw.com   Francis McConville, Esq.   fmcconville@faruqilaw.com   Telephone: (877) 247-4292 or (212) 983-9330  

SOURCE Faruqi & Faruqi, LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,374.76 +23.38 0.14%
S&P 500 1,951.13 +2.27 0.12%
NASDAQ 4,733.4970 -16.4820 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs